摘要
恶性胶质瘤是人类最致命的肿瘤之一,因其血管丰富和弥漫浸润性生长,使得手术不能全部切除并极易复发,患者预后差.因胶质瘤干细胞（GSCs）是胶质瘤发生、发展的源头,因而越来越多的受到关注.干细胞标志物CD133广泛表达于人体多种肿瘤中,同时,它也足研究得最多且应用最广泛的胶质瘤干细胞表面标志物.了解CD133＋胶质瘤干细胞在胶质瘤中的分布可为临床靶向治疗恶性胶质瘤提供依据.
Malignant glioma is one of the most lethal human tumor.Its rich blood vessels and diffuse infiltrative growth make glioma unresect and relapse,and the patients always have poor prognosis.Glioma stem cells （GSCs） are considered to be the source of human glioma development and are getting more and more attention.Stem cell marker CD133 is widely expressed in many human tumors.Meanwhile,it is also the most studied and widely used glioma stem cell surface marker.Understanding the distribution of CD133 ＋ glioma in glioma stem cells may provide the basis for clinical targeted treatment of malignant glioma.
出处
《国际免疫学杂志》
CAS
2016年第5期518-521,共4页
International Journal of Immunology
